Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.24B |
| 2 |
Microsoft
MSFT
|
+$433M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$419M |
| 4 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$332M |
| 5 |
RTX Corp
RTX
|
+$322M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AABA
Altaba Inc
AABA
|
+$267M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$181M |
| 3 |
BCR
CR Bard Inc.
BCR
|
+$134M |
| 4 |
IQVIA
IQV
|
+$134M |
| 5 |
LVLT
Level 3 Communications Inc
LVLT
|
+$121M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.07% |
| 2 | Financials | 5.97% |
| 3 | Healthcare | 5.8% |
| 4 | Consumer Discretionary | 5.2% |
| 5 | Communication Services | 4.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5851
CALL
iShares US Financials ETF
IYF
$4.67B
| $36K | ﹤0.01% |
600
| – | – |
|
5852
Standard BioTools
LAB
$340M
| $36K | ﹤0.01% |
6,150
+4,427
| +257% | +$24.2K |
|
5853
CALL
Lesaka Technologies
LSAK
$396M
| $36K | ﹤0.01% |
+3,000
| New | +$30.4K |
|
5854
MediciNova
MNOV
$65.5M
| $36K | ﹤0.01% |
5,561
+4,373
| +368% | +$29K |
|
5855
Northrim BanCorp
NRIM
$590M
| $36K | ﹤0.01% |
4,300
+3,668
| +580% | +$32.1K |
|
5856
PUT
SFL Corp
SFL
$1.64B
| $36K | ﹤0.01% |
2,300
+1,400
| +156% | +$21K |
|
5857
Superior Group of Companies
SGC
$185M
| $36K | ﹤0.01% |
1,341
+1,138
| +561% | +$27.9K |
|
|
SRGA
5858
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $36K | ﹤0.01% |
292
+249
| +579% | +$34.2K |
|
|
HBMD
5859
DELISTED
Howard Bancorp, Inc. Common Stock
HBMD
| $36K | ﹤0.01% |
1,631
+1,127
| +224% | +$24.1K |
|
|
XONE
5860
CALL
DELISTED
The ExOne Company
XONE
| $36K | ﹤0.01% |
4,300
-5,000
| -54% | -$52.7K |
|
|
CNBKA
5861
DELISTED
Century Bancorp Inc/Mass
CNBKA
| $36K | ﹤0.01% |
464
+396
| +582% | +$33.4K |
|
|
RST
5862
DELISTED
ROSETTA STONE INC
RST
| $36K | ﹤0.01% |
2,887
+2,127
| +280% | +$23.7K |
|
|
PETX
5863
DELISTED
Aratana Therapeutics, Inc.
PETX
| $36K | ﹤0.01% |
6,735
+5,244
| +352% | +$32.1K |
|
|
AVHI
5864
DELISTED
A V Homes, Inc.
AVHI
| $36K | ﹤0.01% |
2,212
+510
| +30% | +$8.74K |
|
|
LAYN
5865
DELISTED
Layne Christensen Co
LAYN
| $36K | ﹤0.01% |
2,862
+2,442
| +581% | +$31.3K |
|
|
DCM
5866
DELISTED
NTT DOCOMO, Inc.
DCM
| $36K | ﹤0.01% |
+1,508
| New | +$36.7K |
|
5867
Allient
ALNT
$1.49B
| $35K | ﹤0.01% |
1,575
+880
| +127% | +$17.9K |
|
5868
Alto Ingredients
ALTO
$369M
| $35K | ﹤0.01% |
7,682
+6,033
| +366% | +$28.6K |
|
5869
Ardelyx
ARDX
$1.22B
| $35K | ﹤0.01% |
5,298
-22,904
| -81% | -$136K |
|
5870
Civista Bancshares
CIVB
$604M
| $35K | ﹤0.01% |
1,573
+1,343
| +584% | +$29.9K |
|
5871
PUT
Cinemark Holdings
CNK
$4.24B
| $35K | ﹤0.01% |
+1,000
| New | +$35.5K |
|
|
EXK
5872
CALL
Endeavour Silver
EXK
$2.23B
| $35K | ﹤0.01% |
14,700
-9,600
| -40% | -$21.7K |
|
5873
CALL
IDT Corp
IDT
$1.64B
| $35K | ﹤0.01% |
3,901
+1,064
| +38% | +$11.7K |
|
5874
Kopin
KOPN
$652M
| $35K | ﹤0.01% |
11,106
+9,679
| +678% | +$33.4K |
|
5875
Minerva Neurosciences
NERV
$185M
| $35K | ﹤0.01% |
741
+656
| +772% | +$32.5K |
|
Similar funds
Barclays's Q4 2017 Portfolio in Review
As of Q4 2017, Barclays held 7,416 positions worth $122B, up 26% from $97.1B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays deployed $19.9B of net new capital in Q4 2017, opening 435 new positions and adding to 3,853 existing holdings. Its largest new stake was iShares US Home Construction ETF: 198,606 shares worth $8.68M.
By sector, the portfolio is most concentrated in Technology at 7.1% of assets, up from 6.2% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Altaba Inc, an estimated $267M trimmed.
- Barclays's largest Q4 2017 buy was iShares US Home Construction ETF: 198,606 shares worth $8.68M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.24B increase.
- Barclays's biggest Q4 2017 reduction was Altaba Inc, cutting an estimated $267M.
- Barclays fully exited CR Bard Inc. in Q4 2017, selling an estimated $134M.
- Barclays's ten largest holdings make up 24% of its $122B portfolio in Q4 2017.
- Barclays opened 435 new positions and closed 356 in Q4 2017.
- Barclays's portfolio value rose 26% quarter-over-quarter to $122B.
Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.